Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
24.88
USD
|
+2.26%
|
|
+0.57%
|
-38.37%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
4,331
|
8,716
|
2,455
|
1,139
|
7,023
|
4,656
|
-
|
-
|
Enterprise Value (EV)
1 |
3,877
|
8,837
|
3,322
|
2,470
|
8,315
|
6,074
|
5,902
|
5,587
|
P/E ratio
|
-14.1
x
|
-18.7
x
|
-4.28
x
|
-2.34
x
|
-10.2
x
|
-7.72
x
|
-7.95
x
|
-9.74
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
107
x
|
1,057
x
|
35.2
x
|
14.7
x
|
755
x
|
33.9
x
|
21.6
x
|
8.14
x
|
EV / Revenue
|
95.6
x
|
1,071
x
|
47.7
x
|
31.8
x
|
894
x
|
44.2
x
|
27.4
x
|
9.76
x
|
EV / EBITDA
|
-14.6
x
|
-18.6
x
|
-5.76
x
|
-4.89
x
|
-14
x
|
-11.9
x
|
-12
x
|
-29.4
x
|
EV / FCF
|
-15.1
x
|
-21.7
x
|
-6.5
x
|
-5.82
x
|
-15.7
x
|
-14.1
x
|
-12.9
x
|
-14.9
x
|
FCF Yield
|
-6.61%
|
-4.61%
|
-15.4%
|
-17.2%
|
-6.36%
|
-7.07%
|
-7.75%
|
-6.73%
|
Price to Book
|
9.02
x
|
151
x
|
-2.83
x
|
-0.91
x
|
-
|
-2.99
x
|
-3.55
x
|
-
|
Nbr of stocks (in thousands)
|
123,575
|
122,568
|
147,192
|
149,483
|
173,967
|
187,129
|
-
|
-
|
Reference price
2 |
35.05
|
71.11
|
16.68
|
7.620
|
40.37
|
24.88
|
24.88
|
24.88
|
Announcement Date
|
3/2/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
40.56
|
8.249
|
69.72
|
77.65
|
9.303
|
137.3
|
215.4
|
572.2
|
EBITDA
1 |
-266.2
|
-474.5
|
-576.6
|
-505.4
|
-593
|
-512.4
|
-491.9
|
-189.9
|
EBIT
1 |
-266.2
|
-474.5
|
-576.6
|
-512.2
|
-607.4
|
-552.6
|
-547.3
|
-429.4
|
Operating Margin
|
-656.41%
|
-5,751.99%
|
-827.12%
|
-659.65%
|
-6,528.75%
|
-402.51%
|
-254.08%
|
-75.04%
|
Earnings before Tax (EBT)
1 |
-288.6
|
-505.5
|
-586.5
|
-484.7
|
-653.3
|
-608.5
|
-618.6
|
-548.5
|
Net income
1 |
-260.6
|
-448.7
|
-562.5
|
-481.2
|
-643.2
|
-612.5
|
-583.9
|
-482.4
|
Net margin
|
-642.47%
|
-5,439.74%
|
-806.9%
|
-619.7%
|
-6,913.92%
|
-446.14%
|
-271.05%
|
-84.31%
|
EPS
2 |
-2.480
|
-3.800
|
-3.900
|
-3.260
|
-3.950
|
-3.224
|
-3.130
|
-2.555
|
Free Cash Flow
1 |
-256.2
|
-407.2
|
-511.2
|
-424.3
|
-529
|
-429.3
|
-457.3
|
-376
|
FCF margin
|
-631.72%
|
-4,936.74%
|
-733.23%
|
-546.46%
|
-5,686.62%
|
-312.7%
|
-212.31%
|
-65.71%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
2.344
|
12.89
|
1.694
|
73.75
|
0.338
|
1.87
|
1.826
|
1.641
|
4.091
|
1.745
|
91.95
|
4.263
|
4.271
|
26.82
|
18.7
|
EBITDA
1 |
-149.5
|
-165.6
|
-151
|
-71.78
|
-124.1
|
-129.2
|
-124.5
|
-140.9
|
-156.1
|
-175.1
|
-142.8
|
-141.7
|
-153.4
|
-148.4
|
-
|
EBIT
1 |
-149.5
|
-165.6
|
-151
|
-80.18
|
-124.1
|
-129.2
|
-126.2
|
-146.1
|
-157.7
|
-177.4
|
-117.1
|
-154.5
|
-159.1
|
-98.89
|
-
|
Operating Margin
|
-6,377.94%
|
-1,285.22%
|
-8,914.76%
|
-108.72%
|
-36,715.98%
|
-6,910.8%
|
-6,909.26%
|
-8,903.05%
|
-3,854.61%
|
-10,167.11%
|
-127.3%
|
-3,623.81%
|
-3,725.61%
|
-368.8%
|
-
|
Earnings before Tax (EBT)
1 |
-161
|
-152.3
|
-201.3
|
-2.559
|
-140.2
|
-140.6
|
-142.7
|
-160.7
|
-179.5
|
-170.3
|
-99.74
|
-158.2
|
-164.1
|
-157.8
|
-
|
Net income
1 |
-155.9
|
-147.2
|
-196.4
|
-9.856
|
-137.3
|
-137.6
|
-140.2
|
-157.9
|
-177
|
-168.1
|
-122
|
-164.4
|
-166.9
|
-165.1
|
-
|
Net margin
|
-6,652.52%
|
-1,142.15%
|
-11,593.68%
|
-13.36%
|
-40,632.84%
|
-7,357.81%
|
-7,675.58%
|
-9,622.12%
|
-4,326.55%
|
-9,635.99%
|
-132.71%
|
-3,855.83%
|
-3,906.85%
|
-615.84%
|
-
|
EPS
2 |
-1.060
|
-1.010
|
-1.350
|
-0.0700
|
-0.9300
|
-0.9200
|
-0.9200
|
-0.9800
|
-1.080
|
-0.9600
|
-0.5092
|
-0.9082
|
-0.9307
|
-0.8291
|
-0.7150
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
2/24/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/22/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
121
|
867
|
1,331
|
1,292
|
1,418
|
1,246
|
931
|
Net Cash position
1 |
454
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.2555
x
|
-1.504
x
|
-2.633
x
|
-2.179
x
|
-2.767
x
|
-2.533
x
|
-4.905
x
|
Free Cash Flow
1 |
-256
|
-407
|
-511
|
-424
|
-529
|
-429
|
-457
|
-376
|
ROE (net income / shareholders' equity)
|
-72.1%
|
-192%
|
138%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-47.5%
|
-67.2%
|
-65.5%
|
-58.8%
|
-109%
|
-107%
|
-135%
|
-
|
Assets
1 |
548.3
|
667.6
|
858.2
|
817.9
|
592
|
571.9
|
431.8
|
-
|
Book Value Per Share
2 |
3.890
|
0.4700
|
-5.900
|
-8.330
|
-
|
-8.320
|
-7.010
|
-
|
Cash Flow per Share
2 |
-
|
-3.390
|
-3.450
|
-2.840
|
-3.240
|
-3.510
|
-2.720
|
-
|
Capex
1 |
2.64
|
7.52
|
13.2
|
4.82
|
1.31
|
4.65
|
7.29
|
8.33
|
Capex / Sales
|
6.5%
|
91.14%
|
19%
|
6.21%
|
14.04%
|
3.38%
|
3.38%
|
1.46%
|
Announcement Date
|
3/2/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
24.88
USD Average target price
50.75
USD Spread / Average Target +103.98% Consensus |
1st Jan change
|
Capi.
|
---|
| -38.37% | 4.66B | | -4.66% | 86.13B | | +1.32% | 39.82B | | -19.27% | 30.42B | | +57.86% | 25.23B | | -17.69% | 11.6B | | -43.00% | 11.51B | | -9.14% | 11.95B | | +5.24% | 8.71B | | -8.42% | 8.12B |
Biopharmaceuticals
|